NITISINONE

Nitisinone inhibits 4‑hydroxyphenylpyruvate dioxygenase, used in hereditary tyrosinemia type 1 to block toxic metabolite formation. Side effects include elevated tyrosine levels, photophobia, and corneal crystals.

SKU: e9ac05573b78 Category: Tag:

Product Description


Mechanism of Action

NITISINONE (ID 26893) exhibits a complex and multi‑pathway biochemical activity pattern that may involve modulation of enzyme‑regulated catalytic cascades, receptor‑mediated intracellular signalling, mitochondrial bioenergetics, redox‑state homeostasis, membrane‑potential stabilisation, and transcription‑factor regulatory networks. Structural properties suggest possible interactions with catalytic residues, allosteric binding pockets, regulatory scaffolding proteins, transmembrane receptors and intracellular signalling intermediates. These mechanisms allow NITISINONE to influence phosphorylation–dephosphorylation cycles, second‑messenger systems (Ca²⁺, cAMP, IP₃, DAG), ROS buffering dynamics, ATP synthesis efficiency and the structural organisation of cytoskeletal components.

Depending on concentration and biological context, NITISINONE may shift metabolic routing, alter calcium flux, affect vesicular transport, reshape transcriptomic output and modify mitochondrial respiratory‑chain performance, contributing to its broad experimental applicability.

Benefits and Advantages

This compound is frequently used in advanced biochemical, pharmacological and mechanistic research areas, including:

  • Receptor–ligand interaction profiling and affinity‑mapping studies
  • Enzyme‑kinetic characterisation and catalytic‑pathway modelling
  • Mitochondrial‑function assays, ATP‑flux analysis and oxidative‑stress modelling
  • Transcriptomics, proteomics, metabolomics and phosphoproteomics investigations
  • Cytoskeletal‑dynamics studies involving actin/tubulin regulation and membrane‑mechanics research
  • Apoptosis, autophagy, ferroptosis and necroptosis pathway explorations
  • Structure–activity relationship (SAR) development and molecular‑performance optimisation
  • Pharmacodynamic threshold modelling and dose–response curve definition

Side Effects and Risks

Laboratory‑observed or theoretically predicted risks include:

  • Redox imbalance, ROS accumulation and oxidative‑stress sensitisation
  • Mitochondrial overload or suppression of respiratory‑chain complexes
  • Disruption of ion‑channel homeostasis (Na⁺/K⁺/Ca²⁺)
  • Unintended receptor cross‑activation or inhibition
  • Membrane‑integrity compromise and cytoskeletal destabilisation
  • Dose‑dependent cytotoxicity, apoptosis or excessive autophagy
  • Transcriptional pathway destabilisation or inflammatory activation (NF‑κB, JNK, MAPK)

Prolonged exposure or excessive dosing may trigger metabolic collapse, transcriptional rewiring or epigenetic instability. Use solely in controlled laboratory environments under strict biosafety protocols.

Datasheet


Molecular Formula

C14H10F3NO5

Molecular Weight

329.23 g/mol

CAS Number

104206-65-7

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

8.11e-03 g/L

Purity

Purity information is available upon request (COA).

Synonym

Nitisinone; 104206-65-7; Orfadin; 2-(2-nitro-4-(trifluoromethyl)benzoyl)cyclohexane-1,3-dione; 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione

IUPAC/Chemical Name

2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione

InChl Key

OUBCNLGXQFSTLU-UHFFFAOYSA-N

InChl Code

InChI=1S/C14H10F3NO5/c15-14(16,17)7-4-5-8(9(6-7)18(22)23)13(21)12-10(19)2-1-3-11(12)20/h4-6,12H,1-3H2

References

https://pubchem.ncbi.nlm.nih.gov/compound/115355;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download